Schrödinger teams up with MD An­der­son on WEE1 in­hibitor pro­gram; Amid JAK safe­ty con­cerns, Ab­b­Vie touts new da­ta for Rin­voq 

Physics-based dis­cov­ery out­fit Schrödinger and the Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter an­nounced to­day a two-year re­search col­lab­o­ra­tion — fo­cused on ac­cel­er­at­ing and op­ti­miz­ing de­vel­op­ment of Schrödinger’s in­ves­ti­ga­tion­al WEE1 in­hibitor.

The team, made up of Schrödinger em­ploy­ees and re­searchers with  MD An­der­son’s Trans­la­tion­al Re­search to Ad­vance Ther­a­peu­tics and In­no­va­tion in On­col­o­gy (TRAC­TION) plat­form, will seek to pri­or­i­tize clin­i­cal stud­ies of a WEE1 in­hibitor as a sin­gle agent in cer­tain can­cer in­di­ca­tions and in com­bi­na­tions for de­fined clin­i­cal sub­pop­u­la­tions, ac­cord­ing to a com­pa­ny state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER